Evaluate Vantage Homepage
A move into the larger second-line breast cancer setting is surely on the way for the Astrazeneca and Daiichi drug.
Adagrasib looks better than Amgen’s Lumakras, which could explain why Mirati has been dragging its heels in lung cancer.
The failed Checkmate-651 study hints at a survival benefit in some PD-L1 expressers, but will this be enough to file?
Despite industry outcry, new data question how relevant the rule would have been anyway.
Calliditas is hoping for its first approval, while Abbvie is gearing up to enter the crowded migraine space with an oral anti-CGRP project.
The depressed company’s bempegaldesleukin, which underwhelmed in melanoma, now faces two key near-term clinical data readouts.
Speedy US approval for Amgen’s Lumakras was an embarrassment for Mirati, which has gone quiet as its share price has drifted downwards.
The group hopes phase 2 data will back approval for its amyotrophic lateral sclerosis project AMX0035 after all.
But winning EU approval for the novel anaemia pill was not straightforward, the Japanese firm says.
An evolving virus demands innovative diagnostic technologies.